SPTX
Seaport Therapeutics, Inc.
Price Chart
Latest Quote
$20.45
+0.01 (+0.05%)
Current Price
| Previous Close | $20.44 |
| Open | $21.05 |
| Day High | $21.73 |
| Day Low | $20.07 |
| Volume | 72,046 |
Stock Information
| Shares Outstanding | 53.53M |
| Total Debt | $5.34M |
| Cash Equivalents | $182.60M |
| Net Income | $-87.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.12B |
| EPS (TTM) | $-1.64 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.26B |
| Income | $-87.16M |
| Book/sh | $-44.55 |
| Cash/sh | $3.41 |
| Employees | 58 |
Financial Ratios
| Quick Ratio | 13.07 |
| Current Ratio | 13.24 |
| Debt/Eq | 2.55 |
Returns & Margins
Ownership
| Insider Ownership | 35.06% |
| Institutional Ownership | 31.93% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.45 |
| P/B | -0.47 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $38.00 |
Technical Indicators
| SMA20 | $20.19 |
| SMA50 | $18.26 |
| RSI | 48.08 |
| ATR | 1.9864 |
| Shares Float | 28.29M |
| Short Float | 5.46% |
| Short Ratio | 11.66 |
| Rel Volume | 0.29 |
Performance History
| Week | -3.38% |
| Month | +16.03% |
| YTD | +5.09% |
| 10 Years | +5.09% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $20.85 | 72,300 |
| 2026-07-16 | $19.52 | 96,900 |
| 2026-07-15 | $20.45 | 72,400 |
| 2026-07-14 | $20.44 | 263,100 |
| 2026-07-13 | $20.10 | 63,200 |
| 2026-07-10 | $21.58 | 76,200 |
| 2026-07-09 | $20.51 | 160,100 |
| 2026-07-08 | $21.26 | 223,400 |
| 2026-07-07 | $18.23 | 157,900 |
| 2026-07-06 | $19.37 | 141,900 |
| 2026-07-02 | $20.57 | 220,800 |
| 2026-07-01 | $21.45 | 245,800 |
| 2026-06-30 | $21.72 | 263,900 |
| 2026-06-29 | $22.52 | 232,200 |
| 2026-06-26 | $21.40 | 194,400 |
| 2026-06-25 | $19.36 | 195,000 |
| 2026-06-24 | $19.31 | 202,700 |
| 2026-06-23 | $18.97 | 322,400 |
| 2026-06-22 | $17.99 | 466,900 |
| 2026-06-18 | $18.17 | 1,326,800 |
About Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $87,294,000 | $52,416,000 |
| Other Income Expense | $1,783,000 | - |
| Other Non Operating Income Expenses | $1,783,000 | - |
| Net Non Operating Interest Income Expense | $11,403,000 | $5,537,000 |
| Operating Expense | $87,294,000 | $52,416,000 |
| General And Administrative Expense | $20,981,000 | $27,346,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-74,881,000 | $-46,879,000 |
| Net Interest Income | $11,403,000 | $5,537,000 |
| Interest Income | $11,403,000 | $5,537,000 |
| Normalized Income | $-74,881,000 | $-46,879,000 |
| Net Income From Continuing And Discontinued Operation | $-74,881,000 | $-46,879,000 |
| Total Operating Income As Reported | $-87,294,000 | $-52,416,000 |
| Net Income Common Stockholders | $-74,881,000 | $-46,879,000 |
| Net Income | $-74,881,000 | $-46,879,000 |
| Net Income Including Noncontrolling Interests | $-74,881,000 | $-46,879,000 |
| Net Income Continuous Operations | $-74,881,000 | $-46,879,000 |
| Pretax Income | $-74,108,000 | $-46,879,000 |
| Interest Income Non Operating | $11,403,000 | $5,537,000 |
| Operating Income | $-87,294,000 | $-52,416,000 |
| Per Share | ||
| Diluted EPS | - | $-0.39 |
| Basic EPS | - | $-0.39 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-85,889,000 | $-52,202,000 |
| Reconciled Depreciation | $1,405,000 | $214,000 |
| EBITDA (Bullshit earnings) | $-85,889,000 | $-52,202,000 |
| EBIT | $-87,294,000 | $-52,416,000 |
| Diluted NI Availto Com Stockholders | $-74,881,000 | $-46,879,000 |
| Tax Provision | $773,000 | $0 |
| Research And Development | $66,313,000 | $25,070,000 |
| Selling General And Administration | $20,981,000 | $27,346,000 |
| Other Gand A | $8,181,000 | $6,685,000 |
| Salaries And Wages | $12,800,000 | $20,661,000 |
| Diluted Average Shares | - | $121,377,047 |
| Basic Average Shares | - | $121,377,047 |
Fetched: 2026-05-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-92,545,000 | $-24,849,000 |
| Total Assets | $249,009,000 | $315,777,000 |
| Total Non Current Assets | $25,779,000 | $5,625,000 |
| Other Non Current Assets | $2,884,000 | $454,000 |
| Current Assets | $223,230,000 | $310,152,000 |
| Prepaid Assets | $4,218,000 | $1,053,000 |
| Receivables | $3,029,000 | $0 |
| Taxes Receivable | $1,296,000 | $0 |
| Accrued Interest Receivable | $1,733,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $215,983,000 | $309,099,000 |
| Cash And Cash Equivalents | $46,042,000 | $309,099,000 |
| Debt | ||
| Total Debt | $5,081,000 | $5,006,000 |
| Long Term Debt And Capital Lease Obligation | $3,444,000 | $4,149,000 |
| Current Debt And Capital Lease Obligation | $1,637,000 | $857,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $341,554,000 | $340,626,000 |
| Total Non Current Liabilities Net Minority Interest | $328,772,000 | $329,477,000 |
| Current Liabilities | $12,782,000 | $11,149,000 |
| Payables And Accrued Expenses | $5,953,000 | $7,377,000 |
| Payables | $2,014,000 | $5,084,000 |
| Accounts Payable | $2,007,000 | $4,733,000 |
| Equity | ||
| Common Stock Equity | $-92,545,000 | $-24,849,000 |
| Total Equity Gross Minority Interest | $-92,545,000 | $-24,849,000 |
| Stockholders Equity | $-92,545,000 | $-24,849,000 |
| Gains Losses Not Affecting Retained Earnings | $301,000 | $0 |
| Other Equity Adjustments | $301,000 | - |
| Retained Earnings | $-114,109,000 | $-39,228,000 |
| Preferred Securities Outside Stock Equity | $325,328,000 | $325,328,000 |
| Other | ||
| Ordinary Shares Number | $53,027,817 | $53,027,817 |
| Share Issued | $53,027,817 | $53,027,817 |
| Tangible Book Value | $-92,545,000 | $-24,849,000 |
| Invested Capital | $-92,545,000 | $-24,849,000 |
| Working Capital | $210,448,000 | $299,003,000 |
| Capital Lease Obligations | $5,081,000 | $5,006,000 |
| Total Capitalization | $-92,545,000 | $-24,849,000 |
| Additional Paid In Capital | $21,262,000 | $14,378,000 |
| Capital Stock | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $3,444,000 | $4,149,000 |
| Current Capital Lease Obligation | $1,637,000 | $857,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,192,000 | $2,915,000 |
| Current Accrued Expenses | $3,939,000 | $2,293,000 |
| Dueto Related Parties Current | $7,000 | $351,000 |
| Investments And Advances | $17,670,000 | $0 |
| Net PPE | $5,225,000 | $5,171,000 |
| Accumulated Depreciation | $-989,000 | $-837,000 |
| Gross PPE | $6,214,000 | $6,008,000 |
| Leases | $432,000 | $101,000 |
| Other Properties | $5,756,000 | $5,907,000 |
| Machinery Furniture Equipment | $26,000 | $0 |
| Properties | $0 | $0 |
| Other Short Term Investments | $169,941,000 | $0 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-78,298,000 | $-29,742,000 |
| Operating Activities | ||
| Operating Cash Flow | $-77,942,000 | $-29,629,000 |
| Cash Flow From Continuing Operating Activities | $-77,942,000 | $-29,629,000 |
| Operating Gains Losses | $11,000 | - |
| Investing Activities | ||
| Capital Expenditure | $-356,000 | $-113,000 |
| Investing Cash Flow | $-184,245,000 | $-113,000 |
| Cash Flow From Continuing Investing Activities | $-184,245,000 | $-113,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $0 | $326,100,000 |
| Financing Cash Flow | $-873,000 | $339,295,000 |
| Cash Flow From Continuing Financing Activities | $-873,000 | $339,295,000 |
| Net Other Financing Charges | $-874,000 | $13,195,000 |
| Net Preferred Stock Issuance | $0 | $326,100,000 |
| Preferred Stock Issuance | $0 | $326,100,000 |
| Other | ||
| Income Tax Paid Supplemental Data | $258,000 | $0 |
| End Cash Position | $46,496,000 | $309,553,000 |
| Beginning Cash Position | $309,553,000 | $0 |
| Effect Of Exchange Rate Changes | $3,000 | $0 |
| Changes In Cash | $-263,060,000 | $309,553,000 |
| Proceeds From Stock Option Exercised | $1,000 | $0 |
| Net Investment Purchase And Sale | $-183,889,000 | $0 |
| Sale Of Investment | $212,500,000 | $0 |
| Purchase Of Investment | $-396,389,000 | $0 |
| Net PPE Purchase And Sale | $-356,000 | $-113,000 |
| Purchase Of PPE | $-356,000 | $-113,000 |
| Change In Working Capital | $-7,930,000 | $2,512,000 |
| Change In Other Current Liabilities | $-1,039,000 | $27,000 |
| Change In Other Current Assets | $-1,556,000 | $0 |
| Change In Payables And Accrued Expense | $877,000 | $2,993,000 |
| Change In Accrued Expense | $3,947,000 | $919,000 |
| Change In Payable | $-3,070,000 | $2,074,000 |
| Change In Account Payable | $-2,726,000 | $1,723,000 |
| Change In Prepaid Assets | $-6,212,000 | $-508,000 |
| Stock Based Compensation | $6,883,000 | $14,524,000 |
| Amortization Of Securities | $-3,430,000 | $0 |
| Depreciation Amortization Depletion | $1,405,000 | $214,000 |
| Depreciation And Amortization | $1,405,000 | $214,000 |
| Depreciation | $1,405,000 | $214,000 |
| Gain Loss On Sale Of PPE | $11,000 | $0 |
| Net Income From Continuing Operations | $-74,881,000 | $-46,879,000 |
Fetched: 2026-07-15